Zentalis Pharmaceuticals (ZNTL) Equity Income (2021 - 2023)

Zentalis Pharmaceuticals has reported Equity Income for 3 years, with the latest figure at -$13.7 million in Q2 2023.

• For the quarter ending Q2 2023, Equity Income fell 156.73% year-over-year to -$13.7 million; the trailing twelve-month figure through Mar 2024 stood at -$13.7 million (up 18.63% YoY), and the FY2023 full-year result was -$16.0 million, up 1.65% from the prior year.
• Equity Income for Q2 2023 stood at -$13.7 million, down from -$2.3 million in the prior quarter.
• The five-year high for Equity Income was -$1.8 million in Q1 2022, with the low at -$13.7 million in Q2 2023.
• Average Equity Income over 3 years is -$4.9 million, with a median of -$2.4 million recorded in 2022.
• Year-over-year, Equity Income tumbled 272.58% in 2022 and tumbled 31.92% in 2023.
• Tracing ZNTL's Equity Income over 3 years: stood at -$1.8 million in 2021, then plunged by 272.58% to -$6.8 million in 2022, then slumped by 100.88% to -$13.7 million in 2023.
• The last three Equity Income figures came in at -$13.7 million (Q2 2023), -$2.3 million (Q1 2023), and -$6.8 million (Q4 2022), per Business Quant data.

Peer Comparison